Cargando…

Lung Cancer Assistant: a hybrid clinical decision support application for lung cancer care

Multidisciplinary team (MDT) meetings are becoming the model of care for cancer patients worldwide. While MDTs have improved the quality of cancer care, the meetings impose substantial time pressure on the members, who generally attend several such MDTs. We describe Lung Cancer Assistant (LCA), a cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Sesen, M. Berkan, Peake, Michael D., Banares-Alcantara, Rene, Tse, Donald, Kadir, Timor, Stanley, Roz, Gleeson, Fergus, Brady, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233704/
https://www.ncbi.nlm.nih.gov/pubmed/24990290
http://dx.doi.org/10.1098/rsif.2014.0534
_version_ 1782344767145771008
author Sesen, M. Berkan
Peake, Michael D.
Banares-Alcantara, Rene
Tse, Donald
Kadir, Timor
Stanley, Roz
Gleeson, Fergus
Brady, Michael
author_facet Sesen, M. Berkan
Peake, Michael D.
Banares-Alcantara, Rene
Tse, Donald
Kadir, Timor
Stanley, Roz
Gleeson, Fergus
Brady, Michael
author_sort Sesen, M. Berkan
collection PubMed
description Multidisciplinary team (MDT) meetings are becoming the model of care for cancer patients worldwide. While MDTs have improved the quality of cancer care, the meetings impose substantial time pressure on the members, who generally attend several such MDTs. We describe Lung Cancer Assistant (LCA), a clinical decision support (CDS) prototype designed to assist the experts in the treatment selection decisions in the lung cancer MDTs. A novel feature of LCA is its ability to provide rule-based and probabilistic decision support within a single platform. The guideline-based CDS is based on clinical guideline rules, while the probabilistic CDS is based on a Bayesian network trained on the English Lung Cancer Audit Database (LUCADA). We assess rule-based and probabilistic recommendations based on their concordances with the treatments recorded in LUCADA. Our results reveal that the guideline rule-based recommendations perform well in simulating the recorded treatments with exact and partial concordance rates of 0.57 and 0.79, respectively. On the other hand, the exact and partial concordance rates achieved with probabilistic results are relatively poorer with 0.27 and 0.76. However, probabilistic decision support fulfils a complementary role in providing accurate survival estimations. Compared to recorded treatments, both CDS approaches promote higher resection rates and multimodality treatments.
format Online
Article
Text
id pubmed-4233704
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher The Royal Society
record_format MEDLINE/PubMed
spelling pubmed-42337042014-11-21 Lung Cancer Assistant: a hybrid clinical decision support application for lung cancer care Sesen, M. Berkan Peake, Michael D. Banares-Alcantara, Rene Tse, Donald Kadir, Timor Stanley, Roz Gleeson, Fergus Brady, Michael J R Soc Interface Research Articles Multidisciplinary team (MDT) meetings are becoming the model of care for cancer patients worldwide. While MDTs have improved the quality of cancer care, the meetings impose substantial time pressure on the members, who generally attend several such MDTs. We describe Lung Cancer Assistant (LCA), a clinical decision support (CDS) prototype designed to assist the experts in the treatment selection decisions in the lung cancer MDTs. A novel feature of LCA is its ability to provide rule-based and probabilistic decision support within a single platform. The guideline-based CDS is based on clinical guideline rules, while the probabilistic CDS is based on a Bayesian network trained on the English Lung Cancer Audit Database (LUCADA). We assess rule-based and probabilistic recommendations based on their concordances with the treatments recorded in LUCADA. Our results reveal that the guideline rule-based recommendations perform well in simulating the recorded treatments with exact and partial concordance rates of 0.57 and 0.79, respectively. On the other hand, the exact and partial concordance rates achieved with probabilistic results are relatively poorer with 0.27 and 0.76. However, probabilistic decision support fulfils a complementary role in providing accurate survival estimations. Compared to recorded treatments, both CDS approaches promote higher resection rates and multimodality treatments. The Royal Society 2014-09-06 /pmc/articles/PMC4233704/ /pubmed/24990290 http://dx.doi.org/10.1098/rsif.2014.0534 Text en http://creativecommons.org/licenses/by/3.0/ © 2014 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/3.0/, which permits unrestricted use, provided the original author and source are credited.
spellingShingle Research Articles
Sesen, M. Berkan
Peake, Michael D.
Banares-Alcantara, Rene
Tse, Donald
Kadir, Timor
Stanley, Roz
Gleeson, Fergus
Brady, Michael
Lung Cancer Assistant: a hybrid clinical decision support application for lung cancer care
title Lung Cancer Assistant: a hybrid clinical decision support application for lung cancer care
title_full Lung Cancer Assistant: a hybrid clinical decision support application for lung cancer care
title_fullStr Lung Cancer Assistant: a hybrid clinical decision support application for lung cancer care
title_full_unstemmed Lung Cancer Assistant: a hybrid clinical decision support application for lung cancer care
title_short Lung Cancer Assistant: a hybrid clinical decision support application for lung cancer care
title_sort lung cancer assistant: a hybrid clinical decision support application for lung cancer care
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233704/
https://www.ncbi.nlm.nih.gov/pubmed/24990290
http://dx.doi.org/10.1098/rsif.2014.0534
work_keys_str_mv AT sesenmberkan lungcancerassistantahybridclinicaldecisionsupportapplicationforlungcancercare
AT peakemichaeld lungcancerassistantahybridclinicaldecisionsupportapplicationforlungcancercare
AT banaresalcantararene lungcancerassistantahybridclinicaldecisionsupportapplicationforlungcancercare
AT tsedonald lungcancerassistantahybridclinicaldecisionsupportapplicationforlungcancercare
AT kadirtimor lungcancerassistantahybridclinicaldecisionsupportapplicationforlungcancercare
AT stanleyroz lungcancerassistantahybridclinicaldecisionsupportapplicationforlungcancercare
AT gleesonfergus lungcancerassistantahybridclinicaldecisionsupportapplicationforlungcancercare
AT bradymichael lungcancerassistantahybridclinicaldecisionsupportapplicationforlungcancercare